Abcam, ab315022, Anti-CBLB antibody [EPR28082-32] - BSA and Azide free

Size: 100µg / 1mg
Knockout Tested Rabbit Recombinant Monoclonal CBLB antibody. Carrier free. Suitable for WB and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR28082-32,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab315022 is the carrier-free version of
ab315021
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CBLB also known as Cbl-b or Casitas B-lineage lymphoma-b is an E3 ubiquitin-protein ligase with a mass of approximately 120 kDa. CBLB is required for the regulation of protein degradation and is involved in transferring ubiquitin to target proteins. It is expressed in multiple tissues including the immune cells such as T cells and B cells. This protein contains several functional domains that facilitate interaction with other proteins allowing it to influence various signaling pathways.
Biological function summary
CBLB plays a critical role in immune regulation and is part of the ubiquitin-proteasome system. As a member of the CBL protein family it interacts with several other proteins to form a complex that determines its function. This complex mediates signal transduction and maintains immune homeostasis efforting its regulatory influence over immune cell activation and avoiding excessive immune responses.
Pathways
CBLB integrates into intracellular signaling involving the T-cell receptor (TCR) and B-cell receptor (BCR) pathways. It modulates downstream signaling by finetuning protein levels and activity interfacing with related proteins such as ZAP70 and Syk. By controlling signal thresholds it ensures proper immune responses and prevents autoimmunity maintaining the balance in signal transduction processes.
Altered CBLB activity is associated with autoimmune diseases and certain cancers such as lymphoma. Its dysfunction can lead to improper regulation of immune responses allowing for unchecked immune activation or proliferation of cancer cells. CBLB interacts with other critical proteins like ITK in T cells influencing the development or progression of these diseases by affecting cell signaling dynamics. Understanding CBLB's role could support therapeutic interventions to modulate immune responses effectively.